DATROWAY ® (datopotamab deruxtecan) has been approved in the European Union (EU) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative ...

Daiichi Sankyo seeks Japanese approval for Enhertu to treat patients with HER2 positive metastatic solid tumours: Tokyo Friday, April 25, 2025, 09:00 Hrs [IST] Daiichi Sankyo has ...

Negative Breast Cancer Market Insight, Epidemiology and Market Forecast - 2035" report delivers comprehensive insights into triple-negative breast cancer, i ...

In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in ...

Daiichi Sankyo Co., Ltd. (TSE:4568) shares surged 6.2% after the pharmaceutical company announced robust fourth-quarter earnings that surpassed expectations, coupled with a significant share buyback ...

Despite the positive results, the company has issued cautious guidance for Datroway product sales, projecting only a modest increase from ¥1.4 billion in FY3/25 to ¥4.7 billion in FY3/26.

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

The study enrolled patients with a PD-L1 combined positive score (CPS) of 10 or more, matching Keytruda's label in first-line ...

The DXd ADC portfolio currently consists of ENHERTU, a HER2 directed ADC, and DATROWAY, a TROP2 directed ADC, which are being jointly developed and commercialized globally with AstraZeneca.